Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin breast milk excretion study after single intravenous Contepo dose in healthy lactating women
PACTR202608684346861Phase 4Not yet recruiting
- Sponsor
- Meitheal Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabotegravir, sponsored by Meitheal Pharmaceuticals. Primary endpoint: Pharmacokinetics of ZTI-01 in breast milk. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cabotegravir
Beyond the preview
Go deeper on PACTR202608684346861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608684346861.